Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
With a market cap of 22.73B, Incyte(INCY) trades at $113.92. The stock has a price-to-earnings ratio of 15.21.
On 2026-06-26, Incyte(INCY) stock moved within a range of $108.00 to $115.56. With shares now at $113.92, the stock is trading +5.5% above its intraday low and -1.4% below the session's peak.
Trading volume for Incyte(INCY) stock has reached 3.79M, versus its average volume of 2.16M.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $115.56 and a low of $66.83.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $115.56 and a low of $66.83.
INCY News
Incyte (INCY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...
...
Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the...
Analyst ratings
60%
of 30 ratingsMore INCY News
UBS raised the firm’s price target on Incyte (INCY) to $113 from $103 and keeps a Neutral rating on the shares. The firm sees biopharma value stocks such as Inc...
Incyte (INCY) stock is drawing fresh attention after a run of clinical and regulatory updates, including pivotal lymphoma data, positive rare disease results, e...
In mid-June 2026, Mirum Pharmaceuticals and Incyte reported pivotal PROGRESS Phase 2 data and an FDA Priority Review for zilurgisertib in ultra-rare fibrodyspla...
Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...
In a report released today, Evan Seigerman from BMO Capital upgraded Incyte to a Hold, with a price target of $94.00. Claim 55% Off TipRanks Unlock powerful inv...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.